TNBC, TRIPLE NEGATIVE BREAST CANCER
Clinical trials for TNBC, TRIPLE NEGATIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new TNBC, TRIPLE NEGATIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for TNBC, TRIPLE NEGATIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Targeted combo aims to spare some breast cancer patients from harsher chemo
Disease control Not yet recruitingThis study is testing a new, less intensive treatment approach for early triple-negative breast cancer (TNBC). It combines two targeted drugs to see if they can effectively shrink tumors before surgery for patients selected by specific tumor markers. The goal is to see if this ge…
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: First Hospital of China Medical University • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New hope for tough breast cancer: Immune-Boosting drug tested before surgery
Disease control Not yet recruitingThis study is testing whether adding an immunotherapy drug (toripalimab) to different chemotherapy combinations works better to shrink triple-negative breast cancer tumors before surgery. Researchers want to see which treatment plan is more effective and safer for patients. The g…
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Henan Cancer Hospital • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New drug targets gene flaw in Tough-to-Treat cancers
Disease control Not yet recruitingThis study is testing an investigational drug called SC-101 for people with advanced breast cancer and other solid tumors that have a specific genetic feature called NECTIN4 amplification. About 120 participants whose cancer has progressed after standard treatments will receive w…
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Tianjin ConjuStar Biologics Co., Ltd. • Aim: Disease control
Last updated Mar 31, 2026 12:10 UTC
-
New Two-Drug attack on Tough-to-Treat breast cancer
Disease control Not yet recruitingThis study is testing whether combining two drugs, inavolisib and eribulin, can help control advanced triple-negative breast cancer that has a specific genetic change (PIK3CA mutation) and has worsened after at least one prior treatment. It will enroll about 26 patients to see ho…
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Hu Hai • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New drug trial aims to keep aggressive breast cancer at bay
Disease control Not yet recruitingThis study tests whether a drug called fluzoparib can help control advanced triple-negative breast cancer after initial treatment. It will involve 72 patients whose cancer responded to platinum-based chemotherapy but could still return. The goal is to see if taking fluzoparib as …
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
New Two-Drug attack on aggressive breast cancer
Disease control Not yet recruitingThis study is testing whether combining two drugs, sacituzumab tirumotecan and toripalimab, can help control advanced triple-negative breast cancer that has spread and cannot be removed by surgery. It will involve about 41 women who have not yet received treatment for their advan…
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Mar 23, 2026 15:14 UTC